the patients received either d-penicillamine ( 600 mg/day ) , medroxyprogesterone acetate ( 5 mg/day ) , or a placebo , or no treatment after the d-penicillamine or medroxyprogesterone medication , each period lasting from nine to 15 months .
C0065864
medroxyprogesterone
C0025147
medroxyprogesterone